We are involved in all of the phases of the health product and/or service life cycle (medicine, medical devices, raw materials for pharmaceutical use, in vitro diagnostic devices, biological and biotechnological products, cosmetics, patient health data, clinical trials, e-health, etc.) and for all French and international operators (pharmaceutical laboratories, medical equipment manufacturers, public or private research institutes, academic stakeholders, biotechnology companies, investors, service providers, competitiveness clusters, etc.).
We assist our clients in three strategic dimensions:
Our assets? Lawyers coming from the pharmaceutical industry or from the field ofmedical equipment finance and senior public administration, a strong relationships with administrative bodies in the field of health, new technologies and personal data protection (CNIL) or professional organizations (including LEEM) and a network of international clients and partners which enable us to remain at the forefront of developments in the health sector.
Subscription:
On this topic and many others, please let us know your main areas of interest
to receive selected information.
Renewable energy: De Gaulle Fleurance advised Leroy Merlin on the signing of electricity supply contracts with Voltalia and Photosol
These corporate PPAs will allow the construction of three solar installations in the ...
Hydrogen: De Gaulle Fleurance advised VINCI Concessions within the context of a strategic partnership with Hype
Hype develops and operates the first hydrogen mobility platform that simultaneously i...